Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2447)
All Articles published online
|
Oct 1, 2004 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Jiao HM, Xie PY. Tegaserod inhibits noxious rectal distention induced responses and limbic system c-Fos expression in rats with visceral hypersensitivity. World J Gastroenterol 2004; 10(19): 2836-2841 [PMID: 15334681 DOI: 10.3748/wjg.v10.i19.2836] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v10/i19/2836.htm |
| Number | Citing Articles |
| 1 |
Richard J. Saad. Peripherally Acting Therapies for the Treatment of Irritable Bowel Syndrome. Gastroenterology Clinics of North America 2011; 40(1): 163 doi: 10.1016/j.gtc.2010.12.008
|
| 2 |
Brian E. Lacy, Mark Pimentel, Darren M. Brenner, William D. Chey, Laurie A. Keefer, Millie D. Long, Baha Moshiree. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. American Journal of Gastroenterology 2021; 116(1): 17 doi: 10.14309/ajg.0000000000001036
|
| 3 |
Emily V. Wechsler, Eric D. Shah. Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options. Drugs 2021; 81(17): 1953 doi: 10.1007/s40265-021-01634-7
|
| 4 |
Daniel P Holschneider, Sylvie Bradesi, Emeran A Mayer. The role of experimental models in developing new treatments for irritable bowel syndrome. Expert Review of Gastroenterology & Hepatology 2011; 5(1): 43 doi: 10.1586/egh.10.88
|
| 5 |
Richard Saad, William D Chey. Tegaserod in the Treatment of Irritable Bowel Syndrome with Constipation. Women's Health 2006; 2(1): 29 doi: 10.2217/17455057.2.1.29
|
| 6 |
L. Bueno, F. De Ponti, M. Fried, G. A. Kullak‐ublick, M. A. Kwiatek, D. Pohl, E. M. M. Quigley, J. Tack, N. J. Talley. Serotonergic and non‐serotonergic targets in the pharmacotherapy of visceral hypersensitivity. Neurogastroenterology & Motility 2007; 19(s1): 89 doi: 10.1111/j.1365-2982.2006.00876.x
|
| 7 |
Kwong M Fock, Amy Wagner. Safety, tolerability and satisfaction with tegaserod therapy in Asia–Pacific patients with irritable bowel syndrome with constipation. Journal of Gastroenterology and Hepatology 2007; 22(8): 1190 doi: 10.1111/j.1440-1746.2007.04955.x
|
| 8 |
John McLaughlin, Lesley A Houghton. The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome. Expert Opinion on Drug Safety 2006; 5(2): 313 doi: 10.1517/14740338.5.2.313
|
| 9 |
|
| 10 |
João Vicente Linhares Rodrigues, Luiz C. Bertges, Carolina F.M.G. Pimentel, Priscilla O. Neves, Renata L. Bormann, José Ricci Júnior, Pedro R. Nardelli, Gabriela C. Toledo. TRÂNSITO GASTROINTESTINAL DE Rattus norvegicus (Berkenhout, 1769) (Rodentia:Muridae) APÓS ADMINISTRAÇÃO DE TEGASERODE. GE Jornal Português de Gastrenterologia 2014; 21(4): 138 doi: 10.1016/j.jpg.2014.02.005
|
| 11 |
B. D. CASH, W. D. CHEY. Review article: the role of serotonergic agents in the treatment of patients with primary chronic constipation. Alimentary Pharmacology & Therapeutics 2005; 22(11-12): 1047 doi: 10.1111/j.1365-2036.2005.02696.x
|
| 12 |
Whitney Emerson Steinmetz. Evaluation and management of irritable bowel syndrome. The Nurse Practitioner 2023; 48(8): 30 doi: 10.1097/01.NPR.0000000000000084
|
| 13 |
Gregory S. Sayuk, Jan Tack. Tegaserod: What’s Old Is New Again. Clinical Gastroenterology and Hepatology 2022; 20(10): 2175 doi: 10.1016/j.cgh.2022.01.024
|